Log In Sign up
The largest database of trusted experimental protocols

Anti actin clone c4 08691001 antibody

Manufactured by MP Biomedicals
Visit Supplier
Sourced in Germany

Anti-actin (Clone C4; #08691001) antibody is a monoclonal antibody that recognizes the actin protein. Actin is a ubiquitous and highly conserved cytoskeletal protein found in all eukaryotic cells.

Automatically generated - may contain errors

Lab products found in correlation

Anti p53 9282, by Cell Signaling Technology (2 mentions) Urolithin a, by Santa Cruz Biotechnology (2 mentions) Enterolacton, by Merck Group (2 mentions) S equol, by Santa Cruz Biotechnology (2 mentions) On targetplus lq 020597 01, by Horizon Discovery (2 mentions) Oligofectamine, by Thermo Fisher Scientific (2 mentions) Oxaliplatin, by Merck Group (2 mentions) Ab109520, by Abcam (2 mentions)

Spelling variants of this product

Anti-actin (45 citations) Anti-actin antibody (18 citations) Anti-actin C4 (5 citations) Anti-actin (clone C4; (3 citations) ACTIN (clone C4, (2 citations)

2 protocols using anti actin clone c4 08691001 antibody

1

Investigating Urolithin A and S-equol Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Urolithin A and S-equol (purity ≥98%) were obtained from Santa Cruz (Germany), siRNA targeting human TIGAR (ON-Targetplus; LQ-020597-01), and scrambled control siRNA were purchased from Dharmacon (via THP, Austria), Oligofectamine came from Invitrogen (via Life Tech, Austria) and all other chemicals, including oxaliplatin and enterolacton, were obtained from Sigma–Aldrich (Austria). The primary antibody against p21 (#ab109520) was obtained from Abcam (UK), the anti-p53 (#9282), and anti-TIGAR (#14751), anti-tubulin (#2144) and secondary antibodies were from Cell Signaling Technology (Germany) and the anti-actin (Clone C4; #08691001) antibody was from MP Biomedicals (Germany).
Norden E, & Heiss E.H. (2018). Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells. Carcinogenesis, 40(1), 93-101.
+ Open protocol
+ Expand
2

Investigating Urolithin A and S-equol Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Urolithin A and S-equol (purity ≥98%) were obtained from Santa Cruz (Germany), siRNA targeting human TIGAR (ON-Targetplus; LQ-020597-01), and scrambled control siRNA were purchased from Dharmacon (via THP, Austria), Oligofectamine came from Invitrogen (via Life Tech, Austria) and all other chemicals, including oxaliplatin and enterolacton, were obtained from Sigma–Aldrich (Austria). The primary antibody against p21 (#ab109520) was obtained from Abcam (UK), the anti-p53 (#9282), and anti-TIGAR (#14751), anti-tubulin (#2144) and secondary antibodies were from Cell Signaling Technology (Germany) and the anti-actin (Clone C4; #08691001) antibody was from MP Biomedicals (Germany).
Norden E, & Heiss E.H. (2018). Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells. Carcinogenesis, 40(1), 93-101.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!